Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma
A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic‑Dominant Ocular Melanoma.
This study aims to evaluate a targeted liver‑directed therapy for patients with metastatic uveal (ocular) melanoma predominantly involving the liver, an area where no effective systemic treatment currently exists.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies